February 19, 2022
Article
“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.
January 18, 2022
Article
The combination of abiraterone acetate, prednisolone, and androgen deprivation therapy (ADT) with or without enzalutamide delivers a strong metastasis-free survival boost versus treatment with ADT alone in patients with high-risk non-metastatic prostate cancer.
September 19, 2021
Article
"2 years of abiraterone-based therapy significantly improves metastasis-free survival and overall survival of high-risk nonmetastatic prostate cancer starting androgen deprivation therapy and should be now considered a new standard of care,” said Gerhardt Attard, MD, FRCP, PhD.
July 30, 2021
Article
The combination achieved a high objective response rate among patients previously treated with immune checkpoint inhibitors.